MolPort expansion enables more efficient compound and reagent sourcing in US
E-commerce platform serves scientists by providing a wide selection of compounds from trusted worldwide suppliers for easy search, convenient ordering and hassle-free delivery.
MolPort, a dedicated full-service e-commerce platform with extensive expertise in compound sourcing, has expanded into the US with the opening of MolPort Inc. This new business unit will further streamline the compound ordering process for its many US customers, who will benefit from faster, more efficient ordering and payment procedures, as well as improved customs navigations.
MolPort combines specialized expertise and innovative software tools for compound sourcing with an extensive database of over 7.6 million stock compounds from more than 60 industry-leading suppliers. In doing so, MolPort enables scientists to focus on their research and not on the often lengthy and complex procurement process.
For over a decade, MolPort’s core expertise in compound sourcing has been helping scientists accelerate drug discovery and compound screening programmes. The company provides one of the most trusted and reliable selections of screening compounds and building blocks to benefit computational and medicinal chemists, among others. By combining natural compounds and other small molecules and building blocks from multiple suppliers, scientists are able to place a single order that includes entities from across different catalogues to generate the best library for their requirements.
MolPort consolidates its commercially available compound database by integrating catalogues from multiple suppliers to produce a single searchable e-commerce platform. It is simple and intuitive to use and is updated and synchronized with supplier inventories on a daily basis. The database can be accessed through an advanced and powerful structure search or list search. Ordering can take place via the online e-shop, or integrated with a company’s procurement system. MolPort’s expert customer service team is easy to reach and fully equipped to use and advise on existing database tools to help build customer libraries, as well as create custom solutions for their clients. The expertise and knowledge of the MolPort team means that they are well-placed to consult with customers to precisely understand their requirements, build personalized libraries, and provide detailed product-specific information and integration solutions.
Dr Nicholas Malmquist, Institut Pasteur, commented: “I found MolPort when I was looking to re-source screening hit compounds. The MolPort website is very intuitive and makes it easy to search for exactly what you need or even similar related compounds. The ordering process is very easy and they take care of sourcing and shipping from multiple suppliers. MolPort is my first stop now for sourcing small molecules.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance